Misonix, Inc. (NASDAQ:MSON) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $12.87 and traded as high as $13.01. Misonix shares last traded at $12.73, with a volume of 34,033 shares changing hands.
Separately, BTIG Research reaffirmed a “buy” rating and set a $18.00 price objective on shares of Misonix in a report on Tuesday, October 6th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Misonix presently has a consensus rating of “Buy” and an average price target of $21.00.
The company’s fifty day simple moving average is $13.27 and its 200-day simple moving average is $12.87. The firm has a market capitalization of $221.22 million, a PE ratio of -8.72 and a beta of 1.51. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.13 and a quick ratio of 2.43.
Several hedge funds and other institutional investors have recently modified their holdings of MSON. California Public Employees Retirement System acquired a new stake in shares of Misonix in the second quarter valued at about $398,000. Bank of New York Mellon Corp raised its position in shares of Misonix by 81.8% in the second quarter. Bank of New York Mellon Corp now owns 43,096 shares of the medical equipment provider’s stock valued at $584,000 after buying an additional 19,392 shares during the last quarter. American International Group Inc. raised its position in shares of Misonix by 64.5% in the second quarter. American International Group Inc. now owns 8,841 shares of the medical equipment provider’s stock valued at $120,000 after buying an additional 3,468 shares during the last quarter. Bank of America Corp DE raised its position in shares of Misonix by 57.3% in the second quarter. Bank of America Corp DE now owns 13,744 shares of the medical equipment provider’s stock valued at $186,000 after buying an additional 5,004 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Misonix by 44.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 38,104 shares of the medical equipment provider’s stock valued at $518,000 after buying an additional 11,741 shares during the last quarter. Institutional investors and hedge funds own 39.16% of the company’s stock.
About Misonix (NASDAQ:MSON)
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Read More: Neutral Rating
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.